Phaseline

Targets › SIGMAR2

SIGMAR2: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: the race on SIGMAR2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
University of Pennsylvania[18F]ISO-1
sigma-2 receptor agonist radiotracer
SIGMAR2Phase 1Breast CancerNov 2026

Conditions

Breast Cancer (1)

Modalities

small molecule (1)

Companies

University of Pennsylvania (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.